Hamburg, October 2018 — “Today’s cell culture requires more than technical solutions for optimized growth conditions and efficient contamination prevention,” says Eppendorf´s Business Manager for cell culture products Dr. Patrik Ferreira. “For several years, customers involved in Eppendorf´s development process have reported an increasing demand for devices that provide flexibility, support with increasing documentation demands and use natural resources sustainably. We also noticed more questions regarding a future ´connected lab´ environment during customer contacts in the last two years.” [Read more…]
Cellular Biomedicine Group (CBMG) to Manufacture Kymriah® for Novartis in China
On September 27, 2018, Cellular Biomedicine Group Inc. (NASDAQ: CBMG) announced it entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® in China. [Read more…]
AI & Blockchain Will Be Major Factors In HealthCare Going Forward
Are you familiar with AI and blockchain? As a stakeholder in healthcare, if you’re not you soon will be, according to Dr. Kala Fleming, an innovation leader at IBM. Fleming, a research scientist, strategist, engineer, and tech startup and hackathon advisor known for designing and implementing initiatives that drive adoption of next-generation technologies, works on digital inclusion across the Caribbean, Africa, and in underserved communities in the U.S. “I also work directly with entrepreneurs, advising on their startups, connecting them to resources or helping them apply emerging technologies like AI and blockchain,” she says. [Read more…]
Fate Therapeutics and ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies
Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform
SAN DIEGO, Sept. 17, 2018 — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. [Read more…]
Your Ultimate Guide to Cell and Gene Therapy Conferences
Cell and gene therapy conferences have been rapidly multiplying over the past decade. This article is your ultimate guide to cell and gene therapy conferences worldwide. These conferences include presentations on stem cells, CAR-T, exosomes, and other types of cell and gene therapy applications.
Our goal is for this to be a comprehensive guide to cell and gene therapy events worldwide, so we welcome new additions in the comments below. [Read more…]
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 62
- Next Page »